Citius Pharmaceuticals, Inc.CTXRNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank29
3Y CAGR-65.8%
5Y CAGR-43.5%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-65.8%/yr
vs +98.4%/yr prior
5Y CAGR
-43.5%/yr
Recent deceleration
Acceleration
-164.1pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 1.55% |
| 2024 | -16.72% |
| 2023 | 39.92% |
| 2022 | 38.69% |
| 2021 | 26.90% |
| 2020 | 27.09% |
| 2019 | -3.11% |
| 2018 | 2.50% |
| 2017 | 56.11% |
| 2016 | 215.17% |